-
乳腺癌是全球范围内与女性癌症相关死亡的最常见疾病之一,其发病率与死亡率也逐年增加[1-2]。乳腺癌是一种具有复杂的生物学特征性高度异质性的恶性乳腺肿瘤,不同分子亚型,其治疗方案及预后差异较大。根据其免疫组织化学(免疫组化)雌激素受体(ER)、孕激素受体(PR)、人表皮生长因子受体2(HER-2)及肿瘤增殖抗原指数(Ki-67)表达情况,将乳腺癌分为4种分子亚型,随着驱动基因重要性的不断增强,首先明确判断HER-2状态成为分子分型的重要原则[3]。HER-2阳性病人预示着肿瘤分化较差、病程进展速度更快、转移和复发概率更高以及预后较差[4]。同时,随着曲妥珠单抗等抗HER-2靶向药物不断问世,改变了HER-2阳性乳腺癌病人的治疗策略,改善了病人的预后[5]。既往对HER-2阳性乳腺癌的诊断需要通过手术或穿刺活检等有创检查的方式。MRI检查作为一种重要无创检查方式,已成为癌症早期诊断的一种很有前途的工具[6]。因此,本次研究希望通过无创性多参数乳腺MRI检查,对HER-2阳性乳腺癌作出初步的诊断,以助于乳腺癌病人治疗方案的初步制定与预后评估。
-
2组平均年龄差异无统计学意义(P>0.05);2组MRI定量特征比较:HER-2阳性组长径与阴性组差异无统计学意义(P>0.05),但ADC值高于阴性组(P < 0.05)(见表 1)。ROC曲线下面积(AUC)为0.663(95%CI:0.538~0.789),利用ROC曲线取阈值0.844×10-3mm2/s,其敏感性88.2%、特异性47.5%(见图 1)。
分组 n 年龄/岁 长径/mm ADC值/(×10-3mm2/s) HER-2阳性组 34 49.59±9.30 26.41±10.66 1.01±0.23 HER-2阴性组 40 45.68±9.01 24.10±12.57 0.90±0.16 t — 1.83 0.84 2.48 P — >0.05 >0.05 < 0.05 表 1 HER-2阳性组与阴性组各定量参数比较
-
MRI定性特征方面,HER-2阳性组与阴性组在病灶形态、边缘及TIC曲线类型分布方面差异均无统计学意义(P>0.05);HER-2阳性组病灶呈不规则或分叶形占比85.29%(29/34)、边缘呈不规则或毛刺占比82.35%(28/34)、TIC曲线Ⅲ型占比64.70%(22/34),阴性组病灶呈不规则或分叶形占比67.50%(27/40)、边缘呈不规则或毛刺占比65.00%(26/40)、TIC曲线Ⅲ型占比50%(20/40)。HER-2阳性组在强化方式上与阴性组差异有统计学意义(P < 0.01)。HER-2阳性组环形强化方式占比47.06%(16/34);阴性组占比15.00%(6/40)(见表 2),ROC AUC为0.689(95%CI:0.567~0.811)(见图 1)。
分组 n 形态 边缘 强化方式 TIC曲线 圆形/类圆形 不规则形 分叶形 光滑 不规则 毛刺 均匀 不均匀 环形 Ⅰ型 Ⅱ型 Ⅲ型 HER-2阳性组 34 5 23 6 6 10 18 3 15 16 5 7 22 HER-2阴性组 40 13 20 7 14 10 16 10 24 6 7 13 20 χ2 — 3.38 2.85 9.97 1.75 P — >0.05 >0.05 < 0.01 >0.05 表 2 HER-2阳性组与阴性组各定性参数比较
-
HER-2阳性乳腺癌典型病例:病人女,56岁,病灶呈圆形,边缘光滑,T1WI呈等信号,抑脂T2WI周围呈稍高信号,中央呈等信号,DWI病灶周围弥散受限呈高信号,ADC病灶周围呈低信号,测ADC值1.036×10-3mm2/s,增强扫描病灶呈环形强化,TIC曲线呈Ⅱ型(平台型)(见图 2A~2F)。HER-2阴性乳腺癌典型病例:病人女,48岁,病灶呈椭圆形,边缘光滑,T1WI呈等信号,抑脂T2WI呈不均匀稍高信号,DWI病灶弥散受限呈高信号,ADC病灶呈低信号,测ADC值0.848×10-3mm2/s,增强扫描病灶呈均匀强化,TIC曲线呈Ⅲ型(流出型)(见图 3)。
多参数3.0T MRI在HER-2阳性乳腺癌中的应用
Application value of multi-parameter 3.0T-MRI in HER-2 positive breast cancer
-
摘要:
目的探讨多参数3.0T-MRI对人表皮生长因子受体2(HER-2)阳性乳腺癌诊断的临床应用价值。 方法回顾性分析74例经病理证实的乳腺癌病人影像学特征及临床资料,所有病人术前均行乳腺MRI检查。根据术后病理免疫组织化学HER-2表达情况分为2组,其中HER-2阳性组34例,HER-2阴性组40例。比较2组在病人年龄、病灶长径、形态、边缘、强化方式、ADC值及病灶时间-信号强度曲线(TIC)之间的差异性,并分析HER-2阳性乳腺癌MRI影像特征。 结果HER-2阳性组年龄(49.59±9.30)岁与阴性组年龄(45.68±9.01)岁差异无统计学意义(P>0.05)。HER-2阳性组病灶表观弥散系数值(1.01±0.23)×10-3 mm2/s高于阴性组的(0.90±0.16)×10-3 mm2/s(P < 0.05),ROC曲线下面积(AUC)为0.663(95%CI:0.538~0.789)。HER-2阳性组病灶呈环形强化方式较阴性组多(P < 0.01),AUC为0.689(95%CI:0.567~0.811)。2组病例在病灶长径、形态、边缘、TIC曲线的MRI特征参数方面差异均无统计学意义(P>0.05)。 结论HER-2阳性乳腺癌MRI影像表现具有一定的特征性,为病人术前评估、临床治疗方案制定、预后判断提供重要参考。 -
关键词:
- 乳腺肿瘤 /
- 人表皮生长因子受体2 /
- 磁共振成像
Abstract:ObjectiveTo explore the clinical value of multi-parameter 3.0T-MRI in the diagnosis of human epidermal growth factor receptor 2(HER-2)positive breast cancer. MethodsThe imaging features and clinical data of 74 patients with breast cancer confirmed by pathology were retrospectively analyzed.The breast MRI in all patients were detected before operation.According to the expression of HER-2 detected by postoperative pathological immunohistochemistry, the patients were divided into the HER-2 positive group(34 cases) and HER-2 negative group(40 cases).The differences of the age, length, diameter, shape and edge of lesions, enhancement mode, apparent diffusion coefficient(ADC) value and time-intensity curve(TIC) curve were compared between two groups, and the MRI features of the HER-2 positive breast cancer were analyzed. ResultsThe difference of the age between the HER-2 positive group[(49.59±9.30) years old] and HER-2 negative group[(45.68±9.01) years old] was not statistically significant(P>0.05).The ADC value of lesions in HER-2 positive group[(1.01±0.23)×10-3mm2/s] was higher than that in HER-2 negative group[(0.90±0.16)×10-3mm2/s](P < 0.05), and the area under ROC curve(AUC) was 0.663(95%CI: 0.538-0.789).The ring enhancement patterns of lesions in HER-2 positive group was more than that in HER-2 negative group(P < 0.01), and AUC was 0.689(95%CI: 0.567-0.811).The differences of the length, diameter, shape and edge of lesions, and MRI characteristic parameters of TIC curve were not statistically significant between two groups(P>0.05). ConclusionsThe MRI findings of the HER-2 positive breast cancer have certain characteristics, which can provide an important reference for the preoperative evaluation, clinical treatment and prognosis of patients. -
表 1 HER-2阳性组与阴性组各定量参数比较
分组 n 年龄/岁 长径/mm ADC值/(×10-3mm2/s) HER-2阳性组 34 49.59±9.30 26.41±10.66 1.01±0.23 HER-2阴性组 40 45.68±9.01 24.10±12.57 0.90±0.16 t — 1.83 0.84 2.48 P — >0.05 >0.05 < 0.05 表 2 HER-2阳性组与阴性组各定性参数比较
分组 n 形态 边缘 强化方式 TIC曲线 圆形/类圆形 不规则形 分叶形 光滑 不规则 毛刺 均匀 不均匀 环形 Ⅰ型 Ⅱ型 Ⅲ型 HER-2阳性组 34 5 23 6 6 10 18 3 15 16 5 7 22 HER-2阴性组 40 13 20 7 14 10 16 10 24 6 7 13 20 χ2 — 3.38 2.85 9.97 1.75 P — >0.05 >0.05 < 0.01 >0.05 -
[1] TORRE LA, ISLAMI F, SIEGEL RL, et al. Global cancer in women: burden and trends[J]. Cancer Epidemiol Biomarkers Prev, 2017, 26(4): 444. doi: 10.1158/1055-9965.EPI-16-0858 [2] ANASTASIADI Z, LIANOS GD, IGNATIADOU E, et al. Breast cancer in young women: an overview[J]. Updates Surg, 2017, 69(3): 313. doi: 10.1007/s13304-017-0424-1 [3] SHI P, CHEN C, YAO Y. Correlation between HER-2 gene amplification or protein expression and clinical pathological features of breast cancer[J]. Cancer Biother Radiopharm, 2019, 34(1): 42. doi: 10.1089/cbr.2018.2576 [4] 郭晨明, 吴楠, 郭丽英. 我国HER-2阳性乳腺癌预后影响因素的Meta分析[J]. 中国普通外科杂志, 2016, 25(2): 264. [5] DI OTO E, BRANDES AA, CUCCHI MC, et al. Prognostic impact of HER-2 Subclonal Amplification in breast cancer[J]. Virchows Arch, 2017;471(3): 313. doi: 10.1007/s00428-017-2151-x [6] 张俊杰, 杨晓棠, 杜笑松, 等. 隐匿性乳腺癌的MRI表现及临床病理特征[J]. 中华肿瘤杂志, 2018, 40(1): 40. [7] WAKS AG, WINER EP. Breast cancer treatment: A review[J]. JAMA, 2019, 321(3): 288. doi: 10.1001/jama.2018.19323 [8] LI X, ZHAO C, SU C, et al. Epidemiological study of HER-2 mutations among EGFR wild-type lung adenocarcinoma patients in China[J]. BMC Cancer, 2016, 16(1): 828. doi: 10.1186/s12885-016-2875-z [9] NITTA H, KELLY BD, ALLRED C, et al. The assessment of HER2 status in breast cancer: the past, the present, and the future[J]. Pathol Int, 2016, 66(6): 313. doi: 10.1111/pin.12407 [10] 江泽飞, 邵志敏, 徐兵河, 等. 人表皮生长因子受体2阳性乳腺癌临床诊疗专家共识2016[J]. 中华医学杂志, 2016, 96(14): 1091. doi: 10.3760/cma.j.issn.0376-2491.2016.14.006 [11] 陶维静, 胡春洪, 柏根基, 等. 乳腺癌MRI强化特征与免疫组织化学相关性分析[J]. 临床放射学杂志, 2016, 35(5): 706. [12] MANNELLI L, NOUGARET S, VARGAS HA, et al. Advances in diffusion weighted imaging[J]. Radiologic clinics of North America, 2015, 53: 569. doi: 10.1016/j.rcl.2015.01.002 [13] 程雪, 余日胜, 徐民, 等. 乳腺癌的功能磁共振成像征象与人表皮生长因子受体2表达差异的相关性分析[J]. 中华医学杂志, 2019, 99(31): 2440. doi: 10.3760/cma.j.issn.0376-2491.2019.31.007 [14] 张丽, 韩立新, 曹惠霞, 等. 3.0T磁共振扩散加权成像和VIBRANT动态增强在鉴别乳腺腺病与乳腺癌中的价值[J]. 临床放射学杂志, 2017, 36(3): 342. [15] 陈倩, 沈玉英, 蔡庆, 等. 乳腺癌MRI表现与CerbB-2、Ki-67表达的相关性研究[J]. 临床放射学杂志, 2016, 35(10): 1486. [16] PARK SH, CHOI HY, HAHN SY. Correlations between apparent diffusion coefficient values of invasive ductal carcinoma and pathologic factors on diffusion weighted MRI at 3.0 Tesla[J]. JMRI, 2015, 41(1): 175. doi: 10.1002/jmri.24519 [17] 李敏红, 陈德基, 罗永良, 等. 乳腺癌的MRI影像学特征与细胞分子表型之间的相关性研究[J]. 临床放射学杂志, 2015, 34(1): 36. [18] LI X, LI Y, ZHU Y, et al. Association between enhancement patterns and parameters of contrast-enhanced ultrasound and microvessel distribution in breast cancer[J]. Oncol Lett, 2018, 15(4): 5643. [19] 孙双燕, 杨长良, 黄志成, 等. 不同分子亚型乳腺癌MRI特征分析[J]. 中国临床医学影像杂志, 2017, 28(5): 327. doi: 10.3969/j.issn.1008-1062.2017.05.007 [20] HA R, JIN B, MANGO V, et al. Breast cancer molecular subtype as a predictor of the utility of preoperative MRI[J]. AJR, 2015, 204(6): 1354. doi: 10.2214/AJR.14.13666 [21] 郭斌. 乳腺癌病人腋窝淋巴结转移相关因素分析[J]. 蚌埠医学院学报, 2021, 46(2): 206.